Glenmark Pharma rises on receiving marketing approval for Ryaltris in 13 EU and UK nations

Glenmark Pharma rises on receiving marketing approval for Ryaltris in 13 EU and UK nations

Shruti Dahiwal
/ Categories: Trending, Mindshare

Post this approval, the pharmaceutical company shall launch Ryaltris directly in the markets of the Czech Republic, Slovakia, Poland, and the UK.

Glenmark Pharmaceuticals Limited, a leading pharmaceutical company, announced this morning that it has received marketing approval for Ryaltris, a fixed-dose combination nasal spray in 13 countries across the EU and UK.  

Post this approval, the pharmaceutical company shall launch Ryaltris directly in the markets of the Czech Republic, Slovakia, Poland, and the UK. In the rest of Europe, the marketing will be done by the Menarini Group as part of its exclusive licensing agreement with Glenmark. Furthermore, for the commercialization of Ryaltris in the US and Canada, the company has collaborated with Hikma Pharmaceuticals PLC and Bausch Health respectively. 

The approved formulation- Ryaltris, helps relieve symptoms of allergic rhinitis, which includes the stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes. It is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children above 12 years of age.  

Owing to this development, at 12.06 pm, the share price of Glenmark Pharmaceuticals Limited was up by 1.3 per cent, trading at Rs 515.85 as against the previous day’s closing price of Rs 509.2 on BSE.   

Previous Article Persistent Systems share price rises 4 per cent on strategic acquisitions
Next Article Aurionpro Solutions bags order worth Rs 40 crore from Haryana State Transport
Rate this article:
4.3

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR